DB:YTSN

Stock Analysis Report

Executive Summary

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Kuros Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: YTSN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

YTSN

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-69.4%

YTSN

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: YTSN underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: YTSN underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

YTSNIndustryMarket
7 Day0%-2.3%-0.2%
30 Day0%-3.2%0.3%
90 Day5.4%6.3%3.7%
1 Year-67.8%-69.4%8.6%8.4%17.2%13.7%
3 Year-90.7%-91.4%44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Kuros Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kuros Biosciences undervalued compared to its fair value and its price relative to the market?

0.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate YTSN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate YTSN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: YTSN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: YTSN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate YTSN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: YTSN is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Kuros Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

8.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: YTSN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YTSN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YTSN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YTSN's revenue (38.6% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: YTSN's revenue (38.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if YTSN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Kuros Biosciences performed over the past 5 years?

2.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: YTSN is currently unprofitable.

Growing Profit Margin: YTSN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YTSN is unprofitable, but has reduced losses over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare YTSN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YTSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: YTSN has a negative Return on Equity (-16.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Kuros Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: YTSN's short term assets (CHF14.4M) exceed its short term liabilities (CHF3.1M).

Long Term Liabilities: YTSN's short term assets (CHF14.4M) exceed its long term liabilities (CHF6.8M).


Debt to Equity History and Analysis

Debt Level: YTSN's debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if YTSN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: YTSN has a low level of unsold assets or inventory.

Debt Coverage by Assets: YTSN's debt is covered by short term assets (assets are 35x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YTSN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if YTSN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Kuros Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate YTSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate YTSN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YTSN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YTSN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of YTSN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Joost de Bruijn (53yo)

1.8yrs

Tenure

CHF593,352

Compensation

Prof. Joost D. de Bruijn, B.Sc. Ph.D., has been Chief Executive Officer of Kuros Biosciences AG since December 4, 2017 and its Director since June 14, 2018. Prof. Dr. de Bruijn served as the Chief Executiv ...


CEO Compensation Analysis

Compensation vs Market: Joost's total compensation ($USD599.28K) is above average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Insufficient data to compare Joost's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Joost de Bruijn
CEO & Director1.8yrsCHF593.35kno data
Frank-Jan van der Velden
Head of Business Affairs & Finance of Kuros Biosciences BV2.6yrsCHF277.30kno data
Michael Grau
Chief Financial Officer1.6yrsno datano data
Oliver Kronenberg
Senior Legal Counsel0yrsno datano data
Alistair Irvine
Chief Business Officer0yrsCHF2.26mno data
Philippe Saudan
Chief Development Officer3.1yrsCHF383.30kno data
Pascal Longlade
Chief Medical Officer1yrsno datano data
Virginia Jamieson
Consultant1.3yrsno datano data

1.7yrs

Average Tenure

57yo

Average Age

Experienced Management: YTSN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Joost de Bruijn
CEO & Director1.8yrsCHF593.35kno data
Clemens van Blitterswijk
Chairman1.3yrsCHF46.90kno data
Oliver Walker
Independent Non-Executive Director1.3yrsCHF26.90kno data
Jason Hannon
Independent Non-Executive Director1.3yrsCHF15.20kno data
Scott Bruder
Independent Non-Executive Director1.3yrsCHF22.90kno data
Cato Laurentin
Member of Advisory Board0yrsno datano data
Ralph Müller
Member of Advisory Board0yrsno datano data
Norbert Boos
Member of Advisory Board0yrsno datano data
Thomas Steffen
Member of Advisory Board0yrsno datano data
Leanna Caron
Vice Chairman of the Board0yrsCHF44.80kno data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Board: YTSN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.2%.


Top Shareholders

Company Information

Kuros Biosciences AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kuros Biosciences AG
  • Ticker: YTSN
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF56.018m
  • Listing Market Cap: CHF51.655m
  • Shares outstanding: 15.06m
  • Website: https://www.kuros.ch

Number of Employees


Location

  • Kuros Biosciences AG
  • Wagistrasse 25
  • Schlieren
  • Zurich
  • 8952
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSBT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2016
KURNSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJan 2016
YTSNDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2016
0RHRLSE (London Stock Exchange)YesCommon SharesGBCHFJan 2016

Biography

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion; and KUR-112 that consists of a natural healing matrix combined with a targeted bone growth factor intended to be applied as a single percutaneous injection into solitary bone cysts. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore’s Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 21:16
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.